论文部分内容阅读
基于异柠檬酸脱氢酶IDH1突变的新型抗肿瘤抑制剂研究
【机 构】
:
复旦大学药学院药物化学教研室,上海浦东张衡路826号,201203
【出 处】
:
2016年长三角药物化学研讨会
【发表日期】
:
2016年11期
其他文献
The proteasome in ubiquitin-proteasome system (UPS) has been validated as an attractive therapeutic target for cancer therapy since FDA approved Bortezomib,Carfilzomib and Ixazomib for the treatment o
One-pot Synthesis of 4-Oxo-4H-pyrano[3,2-c]quinolines Through Cascade Carbonylation-Sonogashira-Cycl
会议
Construction of DOS library through transition metal catalyzed tandem reactions and its biological a
A small molecules library with structure diversity was constructed through diversity-oriented synthesis (DOS) strategy.1 Seven novel scaffolds were quickly synthesized through transition metal catalyz
Sphingomyelin synthase is a proposed potential therapeutic target for atherosclerosis1,obesity and insulin resistance2.Sphingomyelin(SM) is the most abundant sphingolipids in the cell,with ubiquitous
会议
Cancer metastasis is the major cause of cancer-associated death[1].The molecular mechanism is complex,involving the change of multi-step,multi-stage and multi-gene.Based on biological testing of tumor
The FDA approval of the peptide-based proteasome inhibitors bortezomib,carfilzomib,and ixazomib in 2003,2012,and 2015,respectively,has validated the proteasome as an important target in the treatment
The Design, Synthesis and Biological Evaluation of Pro-EGCG Derivatives as Novel Anti-vitiligo Agent
With aim to overcome the instability and poor membrane permeability of EGCG,1 a series of prodrugs of EGCG and its derivatives (Pro-EGCGs) were designed,synthesized,and biological evaluation for their